Evidence map›Paper›PMID 32614819›Full record

ArticlePLoS neglected tropical diseases2020

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration.

Robert K M Choy, Christopher D Huston

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Use-case scenarios for an anti-Cryptosporidium therapeutic.PLoS neglected tropical diseases · 2021
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert K M ChoyPATH, San Francisco, California, United States of America.ORCID 0000-0002-8441-4029
Christopher D HustonUniversity of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.

Funding

Preclinical optimization of a parasiticidal drug for cryptosporidiosisR01AI143951 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUSTON, CHRISTOPHER D, MEYERS, MARVIN J · 2019 to 2023
$3.3M
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug developmentR21AI141184 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI GRIGGS, DAVID, HUSTON, CHRISTOPHER D · 2019 to 2020
$437k
NIAID NIH HHS R01 AI143951NIAID NIH HHS R21 AI141184
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Tropical MedicineCryptosporidiosisDrug ApprovalDrug DevelopmentHumansUnited StatesUnited States Food and Drug Administration

Identifiers

PMID32614819
PMCPMC7332027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.